Form 4: Altimmune Director John Gill Receives Stock Option Grant

Director John Gill was granted 48,800 stock options in Altimmune, Inc. as part of the company's non-employee director compensation policy.

Summary

• Director John Gill received a grant of 48,800 stock options on May 1, 2026.
• The options have an exercise price of $2.82 per share.
• The options vest in substantially equal monthly installments over a 12-month period.
• The expiration date for these options is May 1, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock.
• Dependence on continued service for the vesting of the granted options.

Future Outlook

The options vest over 12 months, indicating a standard retention and incentive structure for non-employee directors.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board members are incentivized to oversee long-term company performance.

Comparison to Industry Standards

• The grant of stock options as part of a non-employee director compensation policy is consistent with standard practices for small-to-mid-cap biotech firms.
• The 12-month vesting schedule is a common, albeit relatively short, retention mechanism compared to multi-year vesting schedules often seen in larger cap companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution impact upon future exercise of options.
• Director: Increased equity stake in the company.

Next Steps

• Vesting of options in monthly installments over the next 12 months.

Key Dates

Keywords

Altimmune, ALT, Form 4, Insider Trading, Stock Options, Director Compensation